In the past few weeks, we’ve seen an abundance of viral-related products, including the FDA’s approval of the EpiPen, and a series of news stories that have been rife with viral-specific news.
But the issue of viral tissue has yet to reach the mainstream press.
We wondered: what’s the story with the anti viral tissue?
What are the viral tissue companies doing about it?
The answer, according to a recent article in Scientific American, is nothing short of miraculous.
According to the article, the industry is trying to “make a living off” its customers.
The article points to the fact that there is a shortage of materials to make the tissue, as well as the fact there is “an abundance of people and products to use” that can’t be found elsewhere.
As a result, the article says, the anti virus company BioCrystals is “pushing hard to get more” products into the market.
As we noted earlier, the issue with the market for anti viral stem cells is that they are so expensive.
The price of each of these cells is $3,000, and some companies have begun making them in their factories.
BioCrystal has begun making its own stem cells, which is a huge step in the right direction, but it still comes at a price.
According a report in Forbes, BioCrystall’s costs have doubled in the last two years alone.
BioCrystals has been working to raise funding for its new manufacturing facility in Texas, but the company’s CEO, Dan Houser, says that he is still looking to raise $100 million to meet the company the needs of its new facility.
The company is currently looking to expand its production capacity to 500,000 cells a day by the end of 2018, with the goal of doubling production by 2019.
Bio Crystals hopes to double its production of anti-viruses by 2019, and Housing says that BioCrysts goal is not just to supply the U.S., but also to produce it in other countries, which are currently “in the dark” about its technology.
The company is already working to help people with chronic diseases.
According the article in Science, Bio Crystal is currently working to create stem cell treatments for some people with inflammatory bowel disease, diabetes, and other conditions.
However, the company also recently made a $1 million donation to a nonprofit organization that helps people with Alzheimer’s disease.